This CME webinar will address genomic testing and interpretation by specifying clinical contexts in which genomic testing may be of diagnostic, prognostic or reproductive planning utility and will be an introduction to the utility of genomics testing for diagnosis of inherited disorders, diagnosis of acquired conditions/neoplasia, reproductive planning, and for prognosis.

1. Recognize types of DNA alterations and the various molecular
   techniques used to detect them
2. Discuss appropriate use of genomics to aid in diagnosis, prognosis
   and predict appropriate therapy.
3. Discuss resources that may help with ordering appropriate clinical genomics tests.
4. Discuss the future of genomics in clinical diagnostics.

Optical coherence tomography (OCT) is one of several exciting, advanced imaging techniques that are beginning to appear in pathology. OCT can rapidly generate photomicrograph-like images directly from tissue, without the need for glass slide histology. Because the images resemble low-to-medium magnification microscope images, pathologists should be able to adapt their existing diagnostic expertise to these novel images. Both in-vivo and specimen (ex-vivo) applications are possible; this means that advanced imaging may permit pathologists to make diagnoses directly on patient images. Advanced imaging therefore represents a fabulous opportunity for pathologists in the 21st century.

This talk will focus on specimen OCT imaging, which is a form of "ex-vivo microscopy". We will present a pathologist-friendly overview of the topic, supplemented with a variety of OCT images presented side-by-side with H&E images, including 3-dimensional OCT images. Next, will be a report of our ongoing work on two clinical applications: breast specimen margins and endometrial cancer depth-of-invasion assessment. Finally, we will present a hypothetical roadmap for creating real clinical applications for OCT, both in-vivo and ex-vivo.

Presenter: Jeffrey L. Fine, MD

This interactive case-based webinar worth 1.5 CME, will answer your common questions and challenges related to HER2 and ER/PgR testing. Two of the ASCO/CAP Guideline authors will facilitate a tumor board-like experience where participants weigh-in on real patient cases. This is a unique opportunity to come together and learn from the experts and other pathologists doing breast predictive factors testing.

As a result of participating in this education activity, you will be able to:

 • Accurately interpret HER2 tests as positive, negative or equivocal
    according to the ASCO/CAP HER2 Guideline criteria.
 • Evaluate and integrate HER2 test results with clinical
    and morphologic findings.
 • Determine appropriate next steps when a HER2 test result
    is discordant with the patient’s profile or other HER2 tests.
 • Apply the ASCO/CAP Guideline criteria for reporting
    HER2 test results.
 • Provide appropriate resolution and clarification in reports
    when HER2 results are equivocal, indeterminate,
    or complex (eg, intratumoral heterogeneity
    or chromosome 17 aneusomy).